Skip to content

Calculus VCT 0% Initial Fee – Limited Time Offer

Calculus Capital is to waive initial fees on its VCT until 5th April 2022, making it one of the most attractive in the current marketplace. The Calculus VCT, which invests alongside Calculus EIS funds, is aiming to deliver an annual dividend of 4.5% of NAV.

Read more
Gaby Tana

Brouhaha Entertainment secures Netflix commission

Netflix has ordered Brouhaha Entertainment’s adaptation of Trent Dalton’s Boy Swallows Universe, more than two years after publisher HarperCollins announced it had sold the screen rights to the author’s debut novel.

Read more

Calculus backs MIP Diagnostics with further funding

MIP Diagnostics, a UK nanotechnology business has secured increased investment of its previous round of funding, totalling £7.3M. The joint investment comes from Mercia Asset Management, Calculus Capital, Downing Ventures and BGF, along with an original angel investor.

Read more

VCTs – Time to diversify

By Oliver Warren, Investor Relations Associate Since April 6 last year, £580m has been invested in VCTs, a record amount at this stage and a more than impressive show of confidence in the UK’s early-stage ecosystem during a period of considerable upheaval. With investors looking to alternative asset classes like venture capital for returns, pension … Continued

The con artist ‘lawyer’ who faked his way to the top – and duped the world

The story behind Wonderhood’s new documentary featured in The Telegraph. He is known as the ‘Devil’s Advocate’, and rarely can there have been a more deliciously appropriate epithet. In a legal career that seemingly knew no bounds, Giovanni di Stefano claimed to have offered counsel to Osama bin Laden, Saddam Hussein, Slobodan Milošević, Arkan, Robert … Continued

Arecor commences US Phase 1 clinical trial of ultra-rapid insulin in combination with an insulin pump

Arecor’s AT247 has the opportunity to revolutionise diabetic management through creating in effect an artificial pancreas through a closed loop system Over 500 million people suffer with diabetes worldwide and AT247 has the potential to make both management easier and improve average blood glucose levels Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to … Continued

CEO Quarterly Blog

Welcome to our final quarterly update of 2021. This has been a record-breaking year for Calculus as we have delivered 11 exits and over £50million back to our investors.  Whilst Calculus’s origins are as a generalist investor, a few years ago we refined our investment strategy to focus on the fastest growing sectors in the UK – … Continued

Venture Capital – Earning its place in a multi asset portfolio

By Matthew Moynes, Assistant Director of Investor Relations, Calculus Capital Synonymous with UK venture capital investing is the attractive tax incentives provided by  HMRC which help stimulate the flow of investor capital into this important asset class. This effective risk mitigation tool can often mean the integrity of the EIS and VCT investment structure can … Continued

Scancell: As Covid mutates, the vaccine makers are adapting too

Scancell featured in the Guardian Focus on the exciting potential of T-cell immunity is spurring the sector on to create a new generation of jabs The speed at which scientists worked to develop the first Covid jabs was unprecedented. Just nine months after the UK went into lockdown, 90-year-old Margaret Keenan officially became the first person in … Continued

Genedrive’s rapid point of care COV19 testing kit receives CE-IVD certification

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to the announcement of 29 November 2021, its rapid point of care Genedrive® COV19-ID Kit has received CE-IVD certification under the European Communities Council Directive 98/79.   The Genedrive® COV19-ID kit is a rapid molecular diagnostic test that delivers positive results as quickly as 7.5 minutes and negative results at 17 minutes.  In … Continued

Calculus invests in Hinterview

UK-based technology company Hinterview has today announced that it has raised £3m in Series A funding. The award-winning video platform for the recruitment sector has experienced soaring demand for their technology, with growth continuing this year as the recruitment industry bounces back in a new era of hybrid-first working. This Series A round, led by … Continued

Scancell: Phase 2 clinical trial of lead immunotherapy product commences

First patient dosed in SCIB1 Phase 2 clinical trial Trial to assess whether the addition of SCIB1 to pembrolizumab (Keytruda®) will result in an improvement in the tumour response rate and overall survival in patients with advanced melanoma Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious … Continued

Spectral MD announce early results from clinical study

Accuracies of 92% and 88% in detection of severe thermal burn injury in adults and children, respectively Article published in Journal of Burn Care and Research on histological burn depth research LONDON, U.K. AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for … Continued